

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 12 February 2016 – Within the Recordati’s share buy-back program announced on 30 April 2015 with the object of purchasing Recordati ordinary shares for the servicing of current and future stock option plans in favor of certain Group employees, the Company informs the following purchase transactions, pursuant to art. 87 bis of Consob Regulation 11971/1999 (“Issuers Regulations”).

SUMMARY OF TRANSACTIONS FROM 4 FEBRUARY 2016 TO 12 FEBRUARY 2016*					
Date	Type of Transaction	Financial Instrument	Quantity	Average price	Consideration Euro
4.2.2016	Purchase	Ord. Shares Recordati	4,000	21.3623	512,694.96
5.2.2016	Purchase	Ord. Shares Recordati	100,000	20.9354	2,093,543.00
8.2.2016	Purchase	Ord. Shares Recordati	90,000	19.7904	1,781,135.10
9.2.2016	Purchase	Ord. Shares Recordati	90,000	19.4665	1,751,984.10
10.2.2016	Purchase	Ord. Shares Recordati	100,000	20.4832	2,048,318.00
11.2.2016	Purchase	Ord. Shares Recordati	100,000	20.5469	2,054,692.00
12.2.2016	Purchase	Ord. Shares Recordati	32,100	20.5736	660,412.88
TOTAL			536,100		10,902,780.04

*Last previous update regarding the on-going buy-back program released to the market on 15 October 2015.

On 12 February 2016, the Company has n. 4,221,458 own shares in Treasury stock which amount to 2.01863% of the current share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2014 was € 987.4 million, operating income was € 231.0 million and net income was € 161.2 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832